Cystic Fibrosis Clinical Trial
Official title:
Disclosure of a Cystic Fibrosis Diagnosis to a Dating Partner
This study will examine the experience of disclosing a cystic fibrosis (CF) diagnosis to a
dating partner. CF has implications for potential life partners (issues of fertility,
decreased life span and an increasing need for medical management with age) that may make
disclosure particularly sensitive. An understanding of the disclosure process may provide
insight into ways health care practitioners can support their patients during this process.
People between 21 and 35 years of age with CF who have been in at least one dating
relationship may be eligible for this study.
Participants are interviewed by telephone about their experiences living with cystic fibrosis
and telling dating partners about their diagnosis. The interview includes questions about:
- Past experiences disclosing their CF diagnosis to a dating partner
- What information was disclosed versus what was not disclosed
- Why certain information was disclosed or not disclosed
- Positive and negative implications of the disclosure or non-disclosure
The interview lasts about 60 minutes and is tape-recorded for later review and analysis.
Cystic fibrosis (CF) is an autosomal recessive chronic medical condition. As medical
treatment is improving more persons with CF are living into adulthood and are entering into
serious dating relationships. A diagnosis of CF has medical implications of concern to
potential life partners including infertility, decreased life span and an increasing need for
medical management with age. In addition, there is a small but non negligible possibility of
future children inheriting the condition. These implications may make this type of disclosure
a particularly important event in one's life and may affect one's disclosure decisions.
Little research has been done on the process of disclosure in this population, and research
specifically on disclosure to dating partners is lacking.
This study seeks to gain insight into the experience of disclosing a CF diagnosis to a dating
partner through semi-structured in-depth phone interviews with approximately 30 persons who
have CF and who vary in gender, age, ethnicity, and severity of their condition. The
interviews will explore general experiences of disclosure to dating partners, will focus on
selective disclosure of certain information to certain recipients, and will explore the
implications of the disclosure or non-disclosure experiences. The qualitative interviews will
be transcribed and subjected to thematic analysis, which will identify common themes across
interviews. An understanding of the disclosure process experienced by persons with cystic
fibrosis may provide insight into ways health care practitioners can support their patients
during this process.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
| Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
| Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
| Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
| Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
| Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
| Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
| Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
| Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
| Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
| Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
| Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
| Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
| Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
| Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |